Cyclo Therapeutics (CYTH) Insider Trading & Ownership $0.72 0.00 (0.00%) As of 03/26/2025 Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cyclo Therapeutics (NASDAQ:CYTH) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage29.78%Number OfInsiders Buying(Last 3 Years)5Amount OfInsider Buying(Last 3 Years)$5.31 MNumber OfInsiders Selling(Last 3 Years)0 Get CYTH Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclo Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CYTH Insider Buying and Selling by Quarter Cyclo Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/1/2023Rafael Holdings, Inc.Major ShareholderBuy4,000,000$1.25$5,000,000.00 4/20/2023Jeffrey TateCOOBuy29,941$0.71$21,258.11 4/20/2023Markus SiegerDirectorBuy59,881$0.71$42,515.51 4/20/2023N Scott FineCEOBuy299,402$0.71$212,575.42 9/21/2022Francis Patrick OstronicDirectorBuy5,000$1.76$8,800.00 9/21/2022Francis Patrick OstronicDirectorBuy5,000$1.76$8,800.00 5/20/2022Francis Patrick OstronicDirectorBuy5,000$2.04$10,200.00 5/16/2022Jeffrey TateCOOBuy3,000$2.12$6,360.00 4/28/2022Jeffrey TateCOOBuy635$2.50$1,587.50 (Data available from 1/1/2013 forward) CYTH Insider Trading Activity - Frequently Asked Questions Who is on Cyclo Therapeutics's Insider Roster? The list of insiders at Cyclo Therapeutics includes Francis Patrick Ostronic, Jeffrey Tate, Markus Sieger, N Scott Fine, and Rafael Holdings, Inc.. Learn more on insiders at CYTH. What percentage of Cyclo Therapeutics stock is owned by insiders? 29.78% of Cyclo Therapeutics stock is owned by insiders. Learn more on CYTH's insider holdings. Which Cyclo Therapeutics insiders have been buying company stock? The following insiders have purchased CYTH shares in the last 24 months: Jeffrey Tate ($21,258.11), Markus Sieger ($42,515.51), N Scott Fine ($212,575.42), and Rafael Holdings, Inc. ($5,000,000.00). How much insider buying is happening at Cyclo Therapeutics? Insiders have purchased a total of 4,389,224 CYTH shares in the last 24 months for a total of $5,276,349.04 bought. Cyclo Therapeutics Key ExecutivesMr. N. Scott Fine (Age 67)CEO & Director Compensation: $569.92kMr. C. E Strattan (Age 78)Founder & Director Mr. Joshua M. Fine (Age 42)CFO & Secretary Compensation: $421.17kMr. Michael Eric Lisjak (Age 50)Global Head of Regulatory Affairs & Senior VP of Business Development Compensation: $430.4kDr. Jeffrey L. Tate Ph.D. (Age 66)COO, Chief Quality Officer & Director Compensation: $255.14kMs. Lori McKennaGlobal Head of Patient AdvocacyDr. Karen Mullen FFPMInterim Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies CCCC Insider Selling OPTN Insider Selling COYA Insider Selling ORMP Insider Selling IMUX Insider Selling CLYM Insider Selling GALT Insider Selling ATOS Insider Selling ZNTL Insider Selling EDIT Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Beware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldJoby Aviation: Operational Momentum vs. Market SentimentMicroStrategy Sees Insider Buy-Sell Action in Q1 This page (NASDAQ:CYTH) was last updated on 4/18/2025 by MarketBeat.com Staff From Our Partners🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYTH Stock Free CYTH Stock Alerts